Toronto Public Health says it observed “many deviations from best practices” during an inspection at the gynecologist's ...

The letter said patients who received endometrial biopsies, IUD insertions or had cervical growths removed at the clinic ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...